AZD 3965
To Order Contact us: stephen@expresspharmapulse.com
AZD-5153 |
|||
| B2020-5 | Biovision | each | EUR 314.4 |
AZD-5069 |
|||
| B2053-25 | Biovision | each | EUR 810 |
AZD-5069 |
|||
| B2053-5 | Biovision | each | EUR 248.4 |
AZD-5438 |
|||
| B2073-25 | Biovision | each | EUR 652.8 |
AZD-5438 |
|||
| B2073-5 | Biovision | each | EUR 210 |
AZD-5582 |
|||
| B2362-1 | Biovision | each | EUR 157.2 |
AZD-5582 |
|||
| B2362-5 | Biovision | each | EUR 444 |
AZD-3229 |
|||
| B2513-1 | Biovision | each | EUR 210 |
AZD-3229 |
|||
| B2513-5 | Biovision | each | EUR 614.4 |
AZD-8186 |
|||
| B1027-25 | Biovision | each | EUR 907.2 |
AZD-8186 |
|||
| B1027-5 | Biovision | each | EUR 274.8 |
AZD-9291 |
|||
| B1104-10 | ApexBio | 10 mg | EUR 192 |
|
Description: AZD-9291 is an irreversible inhibitor of mutant EGFR with IC50 values of 15nM, 17nM and 480nM, respectively for L858R/T790M, ex19del and wild-type EGFR [1].A series of mutations cause the resistance of EGFR, AZD-9291 is developed for an irreversible and selective inhibitor of the mutant EGFR. |
|||
AZD-9291 |
|||
| B1104-5 | ApexBio | 5 mg | EUR 157.2 |
|
Description: AZD-9291 is an irreversible inhibitor of mutant EGFR with IC50 values of 15nM, 17nM and 480nM, respectively for L858R/T790M, ex19del and wild-type EGFR [1].A series of mutations cause the resistance of EGFR, AZD-9291 is developed for an irreversible and selective inhibitor of the mutant EGFR. |
|||
AZD-9291 |
|||
| B1104-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 184.8 |
|
Description: AZD-9291 is an irreversible inhibitor of mutant EGFR with IC50 values of 15nM, 17nM and 480nM, respectively for L858R/T790M, ex19del and wild-type EGFR [1].A series of mutations cause the resistance of EGFR, AZD-9291 is developed for an irreversible and selective inhibitor of the mutant EGFR. |
|||
AZD-9291 |
|||
| B1104-50 | ApexBio | 50 mg | EUR 408 |
|
Description: AZD-9291 is an irreversible inhibitor of mutant EGFR with IC50 values of 15nM, 17nM and 480nM, respectively for L858R/T790M, ex19del and wild-type EGFR [1].A series of mutations cause the resistance of EGFR, AZD-9291 is developed for an irreversible and selective inhibitor of the mutant EGFR. |
|||
AZD-9291 |
|||
| B1104-500 | ApexBio | 500 mg | EUR 1423.2 |
|
Description: AZD-9291 is an irreversible inhibitor of mutant EGFR with IC50 values of 15nM, 17nM and 480nM, respectively for L858R/T790M, ex19del and wild-type EGFR [1].A series of mutations cause the resistance of EGFR, AZD-9291 is developed for an irreversible and selective inhibitor of the mutant EGFR. |
|||
AZD-6482 |
|||
| B1143-25 | Biovision | each | EUR 810 |
AZD-6482 |
|||
| B1143-5 | Biovision | each | EUR 248.4 |
AZD-6738 |
|||
| B1167-25 | Biovision | each | EUR 705.6 |
AZD-0156 |
|||
| B1305-25 | Biovision | each | EUR 614.4 |
AZD-5597 |
|||
| B5926-25 | ApexBio | 25 mg | EUR 1730.4 |
|
Description: AZD-5597 is a potent CDK inhibitor with IC50 values of 2 nM for CDK1 and CDK2, respectively [1]. |
|||
AZD-5597 |
|||
| B5926-5 | ApexBio | 5 mg | EUR 547.2 |
|
Description: AZD-5597 is a potent CDK inhibitor with IC50 values of 2 nM for CDK1 and CDK2, respectively [1]. |
|||
AZD-5597 |
|||
| B5926-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 741.6 |
|
Description: AZD-5597 is a potent CDK inhibitor with IC50 values of 2 nM for CDK1 and CDK2, respectively [1]. |
|||
AZD-3463 |
|||
| 2371-25 | Biovision | each | EUR 548.4 |
AZD-3463 |
|||
| 2371-5 | Biovision | each | EUR 183.6 |
AZD-9291 |
|||
| 2674-25 | Biovision | each | EUR 548.4 |
AZD-9291 |
|||
| 2674-5 | Biovision | each | EUR 183.6 |
AZD-1283 |
|||
| 2838-25 | Biovision | each | EUR 548.4 |
AZD-1283 |
|||
| 2838-5 | Biovision | each | EUR 183.6 |
AZD-5363 |
|||
| B1762-25 | Biovision | each | EUR 705.6 |
AZD-5363 |
|||
| B1762-5 | Biovision | each | EUR 222 |
AZD-3759 |
|||
| 9609-25 | Biovision | each | EUR 757.2 |
AZD-3759 |
|||
| 9609-5 | Biovision | each | EUR 235.2 |
AZD-1981 |
|||
| 9611-25 | Biovision | each | EUR 757.2 |
AZD-1981 |
|||
| 9611-5 | Biovision | each | EUR 235.2 |
AZD-8931 |
|||
| 9659-25 | Biovision | each | EUR 744 |
AZD-8931 |
|||
| 9659-5 | Biovision | each | EUR 248.4 |
AZD-4547 |
|||
| 9403-25 | Biovision | each | EUR 548.4 |
AZD-4547 |
|||
| 9403-5 | Biovision | each | EUR 183.6 |
AZD-7762 |
|||
| 9414-25 | Biovision | each | EUR 496.8 |
AZD-7762 |
|||
| 9414-5 | Biovision | each | EUR 170.4 |
AZD-2014 |
|||
| 9449-25 | Biovision | each | EUR 652.8 |
AZD-2014 |
|||
| 9449-5 | Biovision | each | EUR 210 |
AZD-3463 |
|||
| A8620-10 | ApexBio | 10 mg | EUR 268.8 |
|
Description: Target: ALK, IGF1RIC50: 0.75 nM(Ki)AZD3463 is a novel orally bioavailable ALK/IGF1R inhibitor with Ki value of 0.75 nM. ALK expression is largely restricted to neurons and upregulated in neuroblastoma. |
|||
AZD-3463 |
|||
| A8620-100 | ApexBio | 100 mg | EUR 800.4 |
|
Description: Target: ALK, IGF1RIC50: 0.75 nM(Ki)AZD3463 is a novel orally bioavailable ALK/IGF1R inhibitor with Ki value of 0.75 nM. ALK expression is largely restricted to neurons and upregulated in neuroblastoma. |
|||
AZD-3463 |
|||
| A8620-5 | ApexBio | 5 mg | EUR 192 |
|
Description: Target: ALK, IGF1RIC50: 0.75 nM(Ki)AZD3463 is a novel orally bioavailable ALK/IGF1R inhibitor with Ki value of 0.75 nM. ALK expression is largely restricted to neurons and upregulated in neuroblastoma. |
|||
AZD-3463 |
|||
| A8620-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 212.4 |
|
Description: Target: ALK, IGF1RIC50: 0.75 nM(Ki)AZD3463 is a novel orally bioavailable ALK/IGF1R inhibitor with Ki value of 0.75 nM. ALK expression is largely restricted to neurons and upregulated in neuroblastoma. |
|||
AZD-3463 |
|||
| A8620-50 | ApexBio | 50 mg | EUR 565.2 |
|
Description: Target: ALK, IGF1RIC50: 0.75 nM(Ki)AZD3463 is a novel orally bioavailable ALK/IGF1R inhibitor with Ki value of 0.75 nM. ALK expression is largely restricted to neurons and upregulated in neuroblastoma. |
|||
AZD-5438 |
|||
| A8326-10 | ApexBio | 10 mg | EUR 142.8 |
|
Description: AZD5438 is a potent small molecule inhibitor of cyclin-dependent kinase (CDK) 1, 2 and 9 with half maximal inhibitory concentration IC50 of 16 nmol/L, 6 nmol/L and 20 nmol/L respectively. |
|||
AZD-5438 |
|||
| A8326-100 | ApexBio | 100 mg | EUR 602.4 |
|
Description: AZD5438 is a potent small molecule inhibitor of cyclin-dependent kinase (CDK) 1, 2 and 9 with half maximal inhibitory concentration IC50 of 16 nmol/L, 6 nmol/L and 20 nmol/L respectively. |
|||
AZD-5438 |
|||
| A8326-5.1 | ApexBio | 10 mM (in 1mL DMSO) | EUR 150 |
|
Description: AZD5438 is a potent small molecule inhibitor of cyclin-dependent kinase (CDK) 1, 2 and 9 with half maximal inhibitory concentration IC50 of 16 nmol/L, 6 nmol/L and 20 nmol/L respectively. |
|||
AZD-5438 |
|||
| A8326-50 | ApexBio | 50 mg | EUR 366 |
|
Description: AZD5438 is a potent small molecule inhibitor of cyclin-dependent kinase (CDK) 1, 2 and 9 with half maximal inhibitory concentration IC50 of 16 nmol/L, 6 nmol/L and 20 nmol/L respectively. |
|||
AZD-5991 |
|||
| HY-101533 | MedChemExpress | 5mg | EUR 542.4 |
AZD-1480 |
|||
| HY-10193 | MedChemExpress | 5mg | EUR 142.8 |
AZD-8055 |
|||
| HY-10422 | MedChemExpress | 200mg | EUR 606 |
AZD-7762 |
|||
| HY-10992 | MedChemExpress | 100mg | EUR 834 |
AZD-0364 |
|||
| HY-111483 | MedChemExpress | 50mg | EUR 2402.4 |
AZD-7648 |
|||
| HY-111783 | MedChemExpress | 10mg | EUR 267.6 |
AZD-0284 |
|||
| HY-120384 | MedChemExpress | 100mg | EUR 4675.2 |
AZD-3463 |
|||
| HY-15609 | MedChemExpress | 100mg | EUR 938.4 |
AZD-5069 |
|||
| HY-19855 | MedChemExpress | 5mg | EUR 183.6 |
AZD-6280 |
|||
| HY-19872 | MedChemExpress | 20mg | EUR 4027.2 |
AZD-8835 |
|||
| HY-12869 | MedChemExpress | 25mg | EUR 404.4 |
AZD-2461 |
|||
| HY-13536 | MedChemExpress | 10mM/1mL | EUR 151.2 |
AZD-5438 |
|||
| HY-10012 | MedChemExpress | 10mg | EUR 159.6 |
AZD-8330 |
|||
| GW3804-1 | Glentham Life Sciences | 1 | EUR 204.5 |
AZD-8330 |
|||
| GW3804-10 | Glentham Life Sciences | 10 | EUR 566.4 |
AZD-8330 |
|||
| GW3804-5 | Glentham Life Sciences | 5 | EUR 318.6 |
AZD-8055 |
|||
| GW4102-1 | Glentham Life Sciences | 1 | EUR 138.5 |
AZD-8055 |
|||
| GW4102-10 | Glentham Life Sciences | 10 | EUR 229.3 |
AZD-8055 |
|||
| GW4102-5 | Glentham Life Sciences | 5 | EUR 204.5 |
AZD-1208 |
|||
| GW4562-1 | Glentham Life Sciences | 1 | EUR 138.5 |
AZD-1208 |
|||
| GW4562-10 | Glentham Life Sciences | 10 | EUR 204.5 |
AZD-1208 |
|||
| GW4562-5 | Glentham Life Sciences | 5 | EUR 171.5 |
AZD-2014 |
|||
| GW5430-1 | Glentham Life Sciences | 1 | EUR 204.5 |
AZD-2014 |
|||
| GW5430-10 | Glentham Life Sciences | 10 | EUR 450.8 |
AZD-2014 |
|||
| GW5430-5 | Glentham Life Sciences | 5 | EUR 287 |
AZD 3988 |
|||
| B4944-10 | ApexBio | 10 mg | EUR 699.6 |